Corbus Pharmaceuticals Inc. (NYSE:CRQ), the company behind Arrowhead Pharmaceuticals (NYSEARCA:ARRH), is in the 10th percentile of its industry, according to the company’s latest annual report filed with the Securities and Exchange Commission.

This is a good thing, as the stock is in an important sector for Corbus, which has an annualized gross profit of $1.45 billion.

Corbus shares have been on a tear in the past year, going up over 15% in 2018.

While this is not a record, the company has been in the news for its acquisition of Arrowhead, which saw the company make more than $600 million in sales.

Corbus shares currently trade at $22.51.

While Corbus may have its eye on the top of the heap, it is unlikely to get there without a significant boost from Arrowhead.

Arrowhead was in the midst of a $1 billion buyout last year.

While it is not clear if Corbus will use this cash to build a stronger business, the stock has a good track record in this sector.

Corbutha Pharmaceuticals, Inc. is in 14th place of its sector.

Corbuthas CEO, David J. Orenstein, has been named the CEO of Corbutes Pharmaceuticals.

Odenstein has been the CEO since 2017.

Odonstein has previously worked at Medivation (NASDAQ:MDVA), an online pharmaceutical company that sells an array of prescription medications and medical devices.

Odenstein was also a co-founder of AstraZeneca Pharmaceuticals Ltd., which is also owned by Corbuzys.

In 2016, Odenis helped Astra get its license to grow cannabis for research purposes.

He also served as the chief executive officer at the Canadian biotech firm StemExpress.

Osenstein has had his own share of highs and lows, which include the acquisition of a company in which he has been an investor, the acquisition by Astra and the resignation of former CEO Michael Hulshoff.

Osenstein and Hulschoff are also no strangers to the spotlight.

Hulshon resigned in October of 2016 following the revelation that he was selling shares of Stem Express, which were held by Astrazyn.

Hulson’s resignation came as he was under scrutiny for a lack of transparency around his role in the deal.

In 2017, the Securities & Exchange Commission began investigating Hulsons involvement in the sale of Stems stock.

Hulsons resignation came after he was found to have lied to the Securities&Exchange Commission regarding the deal, which was worth about $1,200 million.

Hulsons role in selling Stems was also the subject of an investigation by the Securities Exchange Commission, which is looking into the sale.HULSONS OWNERSHULSHOFF was fired in January 2017 following the SEC investigation into his role at Stems.

He resigned from his position at Stem and was appointed to the board of directors of Astrazys, the medical cannabis company.

He had been a key figure in the Astrazyls expansion into other drugs.

The stock was trading at $20.65 at the time of his departure.

Corbu shares have since recovered from a $4.50 drop from the previous day.

In the past two years, Corbu has seen a slight rebound from the drop in the stock.

The stock has also risen nearly 4% year-over-year.

It is not immediately clear if this rise is tied to the announcement of an acquisition of the company by Corbus.

Cannabis stocks are a bit tricky for investors to track, but it is clear that Corbu is a hot commodity.

Corbs stock is up about 35% since its last high in February of 2018.

Corbu shares are down more than 20% from its highs of $26.65 a year ago.

There are some good reasons for this, including the fact that the stock price has been declining since March 2018.

Investors should be wary of Corbu because it has a very small market cap, which could make it difficult for it to grow as an investment.